Disclosed are means of enhancing therapeutic effects of fibroblast administration through utilization of extracorporeal shock waves. In one embodiment, enhancement of intravenously administered fibroblast therapeutic activity is accomplished by introducing extracorporeal shock waves to the patient in need of therapy. In one specific embodiment, enhancement of the ability of fibroblasts administered intravenously to treat a condition is accomplished by exposure of areas areas affected by the condition to extracorporeal shock waves. In another specific embodiment, the invention provides transfection of IL-12 and/or IL-23 into fibroblasts to augment regenerative activity, including neuroregenerative and anticancer activity. In further embodiments the invention provides augmentation of regenerative activity by induction of T regulatory cells utilizing IL-35 transfection, wherein said T regulatory cells provide an optimized environment for stimulation of regenerative activity.

The present disclosure provides pharmaceutical compositions prepared using an additive manufacturing process where the active pharmaceutical ingredient has been rendered into the amorphous form or prepared as an amorphous solid dispersion at a temperature below the melting point of the active pharmaceutical ingredient or the glass transition of the physical mixture or composition of the individual components. The present disclosure also provides methods of preparing these compositions by using properties such as the chamber and surface temperature and the electron laser density.

The present disclosure provides pharmaceutical compositions prepared using an additive manufacturing process where the active pharmaceutical ingredient has been rendered into the amorphous form or prepared as an amorphous solid dispersion at a temperature below the melting point of the active pharmaceutical ingredient or the glass transition of the physical mixture or composition of the individual components. The present disclosure also provides methods of preparing these compositions by using properties such as the chamber and surface temperature and the electron laser density.

A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor:

##STR00001##

wherein R.sup.111, R.sup.121, R.sup.131, and R.sup.141 each independently represent a monovalent organic group; p, q, r, and s each independently represent an integer of 0 or 1 to 4; in the case where two or more R.sup.111, R.sup.121, R.sup.131, and R.sup.141 are present, they may be identical to or different from one another or may be bonded to one another to form a ring; A.sup.101 represents a monovalent organic group; and A.sup.102 represents a hydrogen atom or a monovalent organic group). In the method, a photosensitive dye can be decomposed using an energy beam which can penetrate deeper into a living body than near-infrared light and activate the photosensitive dye.

A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor:

##STR00001##

wherein R.sup.111, R.sup.121, R.sup.131, and R.sup.141 each independently represent a monovalent organic group; p, q, r, and s each independently represent an integer of 0 or 1 to 4; in the case where two or more R.sup.111, R.sup.121, R.sup.131, and R.sup.141 are present, they may be identical to or different from one another or may be bonded to one another to form a ring; A.sup.101 represents a monovalent organic group; and A.sup.102 represents a hydrogen atom or a monovalent organic group). In the method, a photosensitive dye can be decomposed using an energy beam which can penetrate deeper into a living body than near-infrared light and activate the photosensitive dye.

A method of macular disease treatment (500) may include introducing nanocapsules into a body of a patient (502). The nanocapsules may be introduced such that the nanocapsules circulate through at least a portion of a body of the patient. A therapeutic substance and a colorant may be encapsulated into the nanocapsules. After a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include emitting a pulsed laser radiation through a pupil of the eye (504). Additionally, after a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include heating the portion of the nanocapsules present in the eye (506) such that at least a portion of the nanocapsules transfer phase and release the therapeutic substance.

Treatment and/or diagnosis of a cancer type characterized by expressing zinc transporter ZIP4. The present invention is directed to nanocarriers functionalized with a ligand capable to bind to the extracellular domain of zinc transporter ZIP4, for use in the treatment and/or diagnosis of a cancer type characterized by expressing ZIP4.

The present invention relates to ultrasound mediated delivery of antimicrobial agents to sites of infection, and particularly for treatment of infections. Thus, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery and preparation for administration of antimicrobial agents and treatment of infections.

Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. The methods of the disclosure induce a systemic allogeneic anti-tumor immune response that results in tumor regression in untreated sites of disease, i.e. non-injected, non-irradiated, etc.

Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. The methods of the disclosure induce a systemic allogeneic anti-tumor immune response that results in tumor regression in untreated sites of disease, i.e. non-injected, non-irradiated, etc.